HIGHBuilt-in & outside partyPipeline
telitacicept
“10-K Item 1A: 'We are substantially dependent on the success of our lead product candidate, telitacicept.'”
VOR · Concentration risk · 10-K extracted
Vor Biopharma (VOR) concentration risks
Updated
The most significant concentration Vor Biopharma discloses is telitacicept, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Vor Biopharma’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
RemeGen
“10-K Item 1A: 'We have no control over the conduct and timing of, ... the trials that RemeGen is conducting for telitacicept.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Vor Biopharma's concentration risk is unusually concentrated for a clinical-stage biopharmaceutical company: the filing states the company is substantially dependent on the success of its lead product candidate, telitacicept, meaning essentially all of the company's near-term value rests on a single asset rather than a diversified pipeline — a structural feature of the business today, though one with both clinical and commercial uncertainty baked in. Compounding that single-asset dependency is a counterparty exposure: Vor has no control over the conduct and timing of the clinical trials that its partner, RemeGen, is running for telitacicept. This means the company's fate is tied not only to the drug candidate itself but also to the operational execution of an external party it does not control. Together, these two exposures are mutually reinforcing rather than independent — a setback in RemeGen's trial conduct would directly threaten the single asset the company is depending on, and there is no second program or partner disclosed to diversify away from either risk. Both exposures are disclosed at the high end of the size band, reflecting how concentrated the company's fortunes currently are in one drug and one partner relationship.
For the engine’s reasoning on VOR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| VOR● | Vor Biopharma Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.